Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China[2]Peking Univ Int Hosp, Dept Hematol, Beijing, Peoples R China[3]Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China[4]Shanghai Tongren Hosp, Dept Hematol, Shanghai, Peoples R China[5]Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China广东省人民医院[6]Peking Univ Peoples Hosp, Dept Hematol, Beijing, Peoples R China[7]Fujian Med Univ Union Hosp, Fujian Inst Hematol, Fuzhou, Fujian, Peoples R China[8]Astellas Pharma Inc, Beijing, Peoples R China[9]Astellas Pharma Inc, Tokyo, Japan[10]Almazov Natl Med Res Ctr, St Petersburg, Russia[11]Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Dept Hematol,Ampang Hosp Selangor, Sarawak, Malaysia[12]State Med Univ, Clin Res Inst Pediat Hematol & Transplantat Name, St Petersburg, Russia[13]Queen Elizabeth Hosp, Dept Hematol, Kota Kinabalu, Sabah, Malaysia[14]Mahidol Univ, Fac Med Siriraj Hosp, Div Hematol, Dept Med, Bangkok, Thailand[15]Skolkovo Inst Sci & Technol, Moscow, Russia[16]Astellas Pharma Inc, Northbrook, IL USA
第一作者机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
推荐引用方式(GB/T 7714):
Wang Jianxiang,Jiang Bin,Li Jian,et al.Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia[J].BLOOD.2021,138:doi:10.1182/blood-2021-145436.
APA:
Wang, Jianxiang,Jiang, Bin,Li, Jian,Liu, Ligen,Du, Xin...&Tiu, Ramon V..(2021).Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia.BLOOD,138,
MLA:
Wang, Jianxiang,et al."Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia".BLOOD 138.(2021)